JP4156665B2 - 薬剤を充填した微粒子を製造するためのシステムと方法 - Google Patents

薬剤を充填した微粒子を製造するためのシステムと方法 Download PDF

Info

Publication number: JP4156665B2
Authority: JP; Japan
Prior art keywords: alginate; icam; drug; mixing chamber; emulsifier
Prior art date: 1995-06-07
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

JP50216797A

Other languages

English (en)

Japanese (ja)

Other versions

JPH11507382A (ja

JPH11507382A5 (2

Inventor

ボンバーガー，デビッド，シー．

キャッツ，ポール，ジー．

スメドレー，マーク，アイ．

ステアーンズ，ポール，シー．

Original Assignee

エスアールアイインターナショナル

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-06-07

Filing date

1996-06-06

Publication date

2008-09-24

1996-06-06 Application filed by エスアールアイインターナショナル filed Critical エスアールアイインターナショナル

1999-06-29 Publication of JPH11507382A publication Critical patent/JPH11507382A/ja

2004-07-29 Publication of JPH11507382A5 publication Critical patent/JPH11507382A5/ja

2008-09-24 Application granted granted Critical

2008-09-24 Publication of JP4156665B2 publication Critical patent/JP4156665B2/ja

2016-06-06 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

239000003814 drug Substances 0.000 title claims abstract description 105
229940079593 drug Drugs 0.000 title claims abstract description 102
239000011859 microparticle Substances 0.000 title claims abstract description 74
238000004519 manufacturing process Methods 0.000 title claims description 17
238000002156 mixing Methods 0.000 claims abstract description 128
102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 claims abstract description 83
108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 claims abstract description 83
239000000243 solution Substances 0.000 claims abstract description 81
238000000034 method Methods 0.000 claims abstract description 49
229920000642 polymer Polymers 0.000 claims abstract description 47
239000003995 emulsifying agent Substances 0.000 claims abstract description 42
239000000839 emulsion Substances 0.000 claims abstract description 42
239000003431 cross linking reagent Substances 0.000 claims abstract description 26
102000004169 proteins and genes Human genes 0.000 claims abstract description 17
108090000623 proteins and genes Proteins 0.000 claims abstract description 17
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 81
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 51
235000010443 alginic acid Nutrition 0.000 claims description 35
229920000615 alginic acid Polymers 0.000 claims description 35
FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical group O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims description 34
229940072056 alginate Drugs 0.000 claims description 33
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 30
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 25
239000002904 solvent Substances 0.000 claims description 25
IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 22
239000010419 fine particle Substances 0.000 claims description 22
235000010413 sodium alginate Nutrition 0.000 claims description 22
239000000661 sodium alginate Substances 0.000 claims description 22
229940005550 sodium alginate Drugs 0.000 claims description 22
238000004132 cross linking Methods 0.000 claims description 19
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical group [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 17
239000001110 calcium chloride Substances 0.000 claims description 15
229910001628 calcium chloride Inorganic materials 0.000 claims description 15
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
235000010410 calcium alginate Nutrition 0.000 claims description 12
239000000648 calcium alginate Substances 0.000 claims description 12
229960002681 calcium alginate Drugs 0.000 claims description 12
239000000203 mixture Substances 0.000 claims description 12
229940008309 acetone / ethanol Drugs 0.000 claims description 8
239000003795 chemical substances by application Substances 0.000 claims description 8
239000012634 fragment Substances 0.000 claims description 8
102000004196 processed proteins & peptides Human genes 0.000 claims description 7
108090000765 processed proteins & peptides Proteins 0.000 claims description 7
VEUACKUBDLVUAC-UHFFFAOYSA-N [Na].[Ca] Chemical compound [Na].[Ca] VEUACKUBDLVUAC-UHFFFAOYSA-N 0.000 claims description 4
HDSBZMRLPLPFLQ-UHFFFAOYSA-N Propylene glycol alginate Chemical compound OC1C(O)C(OC)OC(C(O)=O)C1OC1C(O)C(O)C(C)C(C(=O)OCC(C)O)O1 HDSBZMRLPLPFLQ-UHFFFAOYSA-N 0.000 claims description 3
239000007769 metal material Substances 0.000 claims description 3
235000010408 potassium alginate Nutrition 0.000 claims description 3
239000000737 potassium alginate Substances 0.000 claims description 3
MZYRDLHIWXQJCQ-YZOKENDUSA-L potassium alginate Chemical compound [K+].[K+].O1[C@@H](C([O-])=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C([O-])=O)O[C@@H](O)[C@@H](O)[C@H]1O MZYRDLHIWXQJCQ-YZOKENDUSA-L 0.000 claims description 3
235000010409 propane-1,2-diol alginate Nutrition 0.000 claims description 3
239000000770 propane-1,2-diol alginate Substances 0.000 claims description 3
239000007787 solid Substances 0.000 claims description 2
229960005486 vaccine Drugs 0.000 claims description 2
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims 6
239000012487 rinsing solution Substances 0.000 claims 2
238000013270 controlled release Methods 0.000 abstract description 5
238000012384 transportation and delivery Methods 0.000 abstract description 5
239000012527 feed solution Substances 0.000 abstract 1
239000002245 particle Substances 0.000 description 36
239000004971 Cross linker Substances 0.000 description 20
235000019441 ethanol Nutrition 0.000 description 17
238000011068 loading method Methods 0.000 description 17
230000008569 process Effects 0.000 description 14
238000005406 washing Methods 0.000 description 13
OKHHGHGGPDJQHR-YMOPUZKJSA-L calcium;(2s,3s,4s,5s,6r)-6-[(2r,3s,4r,5s,6r)-2-carboxy-6-[(2r,3s,4r,5s,6r)-2-carboxylato-4,5,6-trihydroxyoxan-3-yl]oxy-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylate Chemical compound [Ca+2].O[C@@H]1[C@H](O)[C@H](O)O[C@@H](C([O-])=O)[C@H]1O[C@H]1[C@@H](O)[C@@H](O)[C@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@H](O2)C([O-])=O)O)[C@H](C(O)=O)O1 OKHHGHGGPDJQHR-YMOPUZKJSA-L 0.000 description 9
238000011049 filling Methods 0.000 description 9
239000007788 liquid Substances 0.000 description 9
239000000463 material Substances 0.000 description 9
239000000047 product Substances 0.000 description 9
238000001035 drying Methods 0.000 description 8
239000004005 microsphere Substances 0.000 description 8
239000000126 substance Substances 0.000 description 8
239000004094 surface-active agent Substances 0.000 description 8
239000007983 Tris buffer Substances 0.000 description 7
230000002776 aggregation Effects 0.000 description 6
239000011324 bead Substances 0.000 description 6
230000015572 biosynthetic process Effects 0.000 description 6
239000012530 fluid Substances 0.000 description 6
238000012377 drug delivery Methods 0.000 description 5
238000002474 experimental method Methods 0.000 description 5
239000000499 gel Substances 0.000 description 5
229910052751 metal Inorganic materials 0.000 description 5
239000002184 metal Substances 0.000 description 5
238000004513 sizing Methods 0.000 description 5
229920006362 Teflon® Polymers 0.000 description 4
238000004220 aggregation Methods 0.000 description 4
239000000872 buffer Substances 0.000 description 4
159000000007 calcium salts Chemical class 0.000 description 4
230000000694 effects Effects 0.000 description 4
238000012360 testing method Methods 0.000 description 4
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
229920004943 Delrin® Polymers 0.000 description 3
238000004458 analytical method Methods 0.000 description 3
239000011575 calcium Substances 0.000 description 3
229910052791 calcium Inorganic materials 0.000 description 3
230000015556 catabolic process Effects 0.000 description 3
210000004027 cell Anatomy 0.000 description 3
238000000576 coating method Methods 0.000 description 3
238000006731 degradation reaction Methods 0.000 description 3
238000009826 distribution Methods 0.000 description 3
238000005538 encapsulation Methods 0.000 description 3
238000005516 engineering process Methods 0.000 description 3
238000001914 filtration Methods 0.000 description 3
239000012467 final product Substances 0.000 description 3
235000013305 food Nutrition 0.000 description 3
230000006870 function Effects 0.000 description 3
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 3
230000004048 modification Effects 0.000 description 3
238000012986 modification Methods 0.000 description 3
210000003928 nasal cavity Anatomy 0.000 description 3
238000001556 precipitation Methods 0.000 description 3
238000011084 recovery Methods 0.000 description 3
238000003860 storage Methods 0.000 description 3
238000012546 transfer Methods 0.000 description 3
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
AEMOLEFTQBMNLQ-AZLKCVHYSA-N (2r,3s,4s,5s,6r)-3,4,5,6-tetrahydroxyoxane-2-carboxylic acid Chemical group O[C@@H]1O[C@@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H]1O AEMOLEFTQBMNLQ-AZLKCVHYSA-N 0.000 description 2
AEMOLEFTQBMNLQ-SYJWYVCOSA-N (2s,3s,4s,5s,6r)-3,4,5,6-tetrahydroxyoxane-2-carboxylic acid Chemical group O[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H]1O AEMOLEFTQBMNLQ-SYJWYVCOSA-N 0.000 description 2
102000009027 Albumins Human genes 0.000 description 2
108010088751 Albumins Proteins 0.000 description 2
102000008186 Collagen Human genes 0.000 description 2
108010035532 Collagen Proteins 0.000 description 2
229920002307 Dextran Polymers 0.000 description 2
241000709661 Enterovirus Species 0.000 description 2
108010010803 Gelatin Proteins 0.000 description 2
229920002148 Gellan gum Polymers 0.000 description 2
241000430519 Human rhinovirus sp. Species 0.000 description 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
229920005654 Sephadex Polymers 0.000 description 2
239000012507 Sephadex™ Substances 0.000 description 2
239000004147 Sorbitan trioleate Substances 0.000 description 2
PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 2
239000004809 Teflon Substances 0.000 description 2
238000005054 agglomeration Methods 0.000 description 2
150000001298 alcohols Chemical class 0.000 description 2
230000035587 bioadhesion Effects 0.000 description 2
239000007853 buffer solution Substances 0.000 description 2
239000001913 cellulose Substances 0.000 description 2
229920002678 cellulose Polymers 0.000 description 2
235000010980 cellulose Nutrition 0.000 description 2
239000007795 chemical reaction product Substances 0.000 description 2
210000004081 cilia Anatomy 0.000 description 2
229920001436 collagen Polymers 0.000 description 2
229920001577 copolymer Polymers 0.000 description 2
230000018044 dehydration Effects 0.000 description 2
238000006297 dehydration reaction Methods 0.000 description 2
238000009513 drug distribution Methods 0.000 description 2
239000002702 enteric coating Substances 0.000 description 2
238000009505 enteric coating Methods 0.000 description 2
238000009472 formulation Methods 0.000 description 2
210000004051 gastric juice Anatomy 0.000 description 2
239000008273 gelatin Substances 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
235000019322 gelatine Nutrition 0.000 description 2
235000011852 gelatine desserts Nutrition 0.000 description 2
235000010492 gellan gum Nutrition 0.000 description 2
239000000216 gellan gum Substances 0.000 description 2
238000009776 industrial production Methods 0.000 description 2
230000003993 interaction Effects 0.000 description 2
238000002386 leaching Methods 0.000 description 2
210000000265 leukocyte Anatomy 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
210000001331 nose Anatomy 0.000 description 2
238000012856 packing Methods 0.000 description 2
102000005962 receptors Human genes 0.000 description 2
108020003175 receptors Proteins 0.000 description 2
229910052708 sodium Inorganic materials 0.000 description 2
239000011734 sodium Substances 0.000 description 2
235000019337 sorbitan trioleate Nutrition 0.000 description 2
229960000391 sorbitan trioleate Drugs 0.000 description 2
239000007921 spray Substances 0.000 description 2
235000010493 xanthan gum Nutrition 0.000 description 2
239000000230 xanthan gum Substances 0.000 description 2
229920001285 xanthan gum Polymers 0.000 description 2
229940082509 xanthan gum Drugs 0.000 description 2
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
101710145634 Antigen 1 Proteins 0.000 description 1
229920002799 BoPET Polymers 0.000 description 1
QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
108050001049 Extracellular proteins Proteins 0.000 description 1
IAJILQKETJEXLJ-SQOUGZDYSA-N L-guluronic acid Chemical group O=C[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O IAJILQKETJEXLJ-SQOUGZDYSA-N 0.000 description 1
102000018697 Membrane Proteins Human genes 0.000 description 1
108010052285 Membrane Proteins Proteins 0.000 description 1
239000005041 Mylar™ Substances 0.000 description 1
102000015731 Peptide Hormones Human genes 0.000 description 1
108010038988 Peptide Hormones Proteins 0.000 description 1
229920001214 Polysorbate 60 Polymers 0.000 description 1
206010061494 Rhinovirus infection Diseases 0.000 description 1
229920002125 Sokalan® Polymers 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
239000002253 acid Substances 0.000 description 1
239000013543 active substance Substances 0.000 description 1
239000000853 adhesive Substances 0.000 description 1
230000001070 adhesive effect Effects 0.000 description 1
150000004781 alginic acids Chemical group 0.000 description 1
150000005215 alkyl ethers Chemical class 0.000 description 1
239000008346 aqueous phase Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
239000003125 aqueous solvent Substances 0.000 description 1
239000012298 atmosphere Substances 0.000 description 1
238000010923 batch production Methods 0.000 description 1
230000008901 benefit Effects 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
229920001222 biopolymer Polymers 0.000 description 1
239000000337 buffer salt Substances 0.000 description 1
239000008366 buffered solution Substances 0.000 description 1
210000004899 c-terminal region Anatomy 0.000 description 1
-1 calcium Chemical class 0.000 description 1
230000017455 cell-cell adhesion Effects 0.000 description 1
230000008859 change Effects 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
238000004140 cleaning Methods 0.000 description 1
239000011243 crosslinked material Substances 0.000 description 1
238000001723 curing Methods 0.000 description 1
230000001086 cytosolic effect Effects 0.000 description 1
230000009849 deactivation Effects 0.000 description 1
238000013461 design Methods 0.000 description 1
239000003599 detergent Substances 0.000 description 1
230000001627 detrimental effect Effects 0.000 description 1
SWXVUIWOUIDPGS-UHFFFAOYSA-N diacetone alcohol Natural products CC(=O)CC(C)(C)O SWXVUIWOUIDPGS-UHFFFAOYSA-N 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
238000010586 diagram Methods 0.000 description 1
230000006806 disease prevention Effects 0.000 description 1
238000004945 emulsification Methods 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
239000012065 filter cake Substances 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000019634 flavors Nutrition 0.000 description 1
238000007429 general method Methods 0.000 description 1
235000021474 generally recognized As safe (food) Nutrition 0.000 description 1
235000021473 generally recognized as safe (food ingredients) Nutrition 0.000 description 1
230000036541 health Effects 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
230000006872 improvement Effects 0.000 description 1
238000011534 incubation Methods 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
102000006495 integrins Human genes 0.000 description 1
108010044426 integrins Proteins 0.000 description 1
230000005732 intercellular adhesion Effects 0.000 description 1
230000016507 interphase Effects 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 description 1
239000003446 ligand Substances 0.000 description 1
210000004698 lymphocyte Anatomy 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
239000012528 membrane Substances 0.000 description 1
210000004379 membrane Anatomy 0.000 description 1
229940071648 metered dose inhaler Drugs 0.000 description 1
239000004570 mortar (masonry) Substances 0.000 description 1
230000000420 mucociliary effect Effects 0.000 description 1
210000004877 mucosa Anatomy 0.000 description 1
230000004682 mucosal barrier function Effects 0.000 description 1
210000003097 mucus Anatomy 0.000 description 1
210000002850 nasal mucosa Anatomy 0.000 description 1
229940097496 nasal spray Drugs 0.000 description 1
239000007922 nasal spray Substances 0.000 description 1
201000009240 nasopharyngitis Diseases 0.000 description 1
210000001989 nasopharynx Anatomy 0.000 description 1
238000006386 neutralization reaction Methods 0.000 description 1
239000012074 organic phase Substances 0.000 description 1
230000037361 pathway Effects 0.000 description 1
239000012071 phase Substances 0.000 description 1
238000005191 phase separation Methods 0.000 description 1
230000035790 physiological processes and functions Effects 0.000 description 1
239000004584 polyacrylic acid Substances 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
239000011148 porous material Substances 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
230000003449 preventive effect Effects 0.000 description 1
230000009467 reduction Effects 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
238000012216 screening Methods 0.000 description 1
150000003384 small molecules Chemical class 0.000 description 1
159000000000 sodium salts Chemical group 0.000 description 1
238000000935 solvent evaporation Methods 0.000 description 1
239000011877 solvent mixture Substances 0.000 description 1
239000012798 spherical particle Substances 0.000 description 1
238000001694 spray drying Methods 0.000 description 1
238000005507 spraying Methods 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
230000003068 static effect Effects 0.000 description 1
238000011146 sterile filtration Methods 0.000 description 1
239000000758 substrate Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
230000008961 swelling Effects 0.000 description 1
229920001059 synthetic polymer Polymers 0.000 description 1
238000012385 systemic delivery Methods 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
239000004753 textile Substances 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
238000004879 turbidimetry Methods 0.000 description 1
210000001944 turbinate Anatomy 0.000 description 1
238000001291 vacuum drying Methods 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
238000003260 vortexing Methods 0.000 description 1
239000002699 waste material Substances 0.000 description 1
230000004580 weight loss Effects 0.000 description 1
238000009736 wetting Methods 0.000 description 1

Images

Classifications

- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2/00—Processes or devices for granulating materials, e.g. fertilisers in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Cell Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Zoology (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

JP50216797A 1995-06-07 1996-06-06 薬剤を充填した微粒子を製造するためのシステムと方法 Expired - Lifetime JP4156665B2 (ja)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US08/480,624 US5879712A (en)	1995-06-07	1995-06-07	Method for producing drug-loaded microparticles and an ICAM-1 dosage form so produced
US08/480,624		1995-06-07
PCT/US1996/010031 WO1996040069A1 (en)	1995-06-07	1996-06-06	System and method for producing drug-loaded microparticles

Publications (3)

Publication Number	Publication Date
JPH11507382A JPH11507382A (ja)	1999-06-29
JPH11507382A5 JPH11507382A5 (2)	2004-07-29
JP4156665B2 true JP4156665B2 (ja)	2008-09-24

Family

ID=23908687

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP50216797A Expired - Lifetime JP4156665B2 (ja)	1995-06-07	1996-06-06	薬剤を充填した微粒子を製造するためのシステムと方法

Country Status (8)

Country	Link
US (3)	US5879712A (2)
EP (1)	EP0833614B1 (2)
JP (1)	JP4156665B2 (2)
AT (1)	ATE353631T1 (2)
CA (1)	CA2224074C (2)
DE (1)	DE69636904T2 (2)
ES (1)	ES2281084T3 (2)
WO (1)	WO1996040069A1 (2)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2141076T3 (es)	1988-09-01	2000-03-16	Bayer Ag	Proteina del receptor de rinovirus humano que inhibe la infectividad del virus.
US6514936B1 (en)	1988-09-01	2003-02-04	Bayer Corporation	Antiviral methods using human rhinovirus receptor (ICAM-1)
US6235313B1 (en)	1992-04-24	2001-05-22	Brown University Research Foundation	Bioadhesive microspheres and their use as drug delivery and imaging systems
US5879712A (en) *	1995-06-07	1999-03-09	Sri International	Method for producing drug-loaded microparticles and an ICAM-1 dosage form so produced
WO1997032596A1 (en)	1996-03-06	1997-09-12	Boehringer Ingelheim Pharmaceuticals, Inc.	Intercellular adhesion molecule powder formulation
US20020182258A1 (en) *	1997-01-22	2002-12-05	Zycos Inc., A Delaware Corporation	Microparticles for delivery of nucleic acid
IT1291559B1 (it) *	1997-04-14	1999-01-11	Univ Degli Studi Milano	Uso di microparticelle su cui sono stati adsorbiti una proteina ed un anticorpo per preparare una composizione farmaceutica somministrabile
US6391452B1 (en)	1997-07-18	2002-05-21	Bayer Corporation	Compositions for nasal drug delivery, methods of making same, and methods of removing residual solvent from pharmaceutical preparations
US6395298B1 (en) *	1997-10-31	2002-05-28	Pharmacia Corporation	Gellan gum tablet coating
CA2308291A1 (en) *	1997-10-31	1999-05-14	Thierry Nivaggioli	Controlled release compositions comprising gellan gum gels
WO1999024159A1 (en) *	1997-11-10	1999-05-20	Quest International B.V.	Encapsulate of active material in alginate matrix
US6485747B1 (en) *	1998-10-30	2002-11-26	Monsanto Company	Coated active tablet(s)
US6248321B1 (en) *	1999-01-14	2001-06-19	Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of Natural Resources, Canadian Forestry Service	Encapsulation of microparticles in teardrop shaped polymer capsules of cellular size
DE19904785A1 (de) *	1999-02-05	2000-08-10	Ulrich Zimmermann	Verfahren zur Herstellung von stabilem Alginatmaterial
US6927223B1 (en)	2000-05-26	2005-08-09	Washington State University Research Foundation	Use of serotonin agents for adjunct therapy in the treatment of cancer
US7118737B2 (en) *	2000-09-08	2006-10-10	Amylin Pharmaceuticals, Inc.	Polymer-modified synthetic proteins
ATE500838T1 (de) *	2000-09-08	2011-03-15	Amylin Pharmaceuticals Inc	ßPSEUDOß-NATIVE CHEMISCHE LIGATION
US7008650B2 (en) *	2001-08-09	2006-03-07	Lam Paul Y S	Compositions for the treatment of acquired immunodeficiency disease
US20050069549A1 (en)	2002-01-14	2005-03-31	William Herman	Targeted ligands
CA2483827C (en) *	2002-04-29	2012-01-24	Amir H. Shojaei	Pharmaceutical formulations with improved bioavailability
US20030206957A1 (en) *	2002-05-06	2003-11-06	Scherr George H.	Orally administered medicament delivery systems
GB2399084B (en) *	2002-07-30	2007-01-31	Univ Liverpool	Porous beads and method of production thereof
SI1551876T1 (sl)	2002-10-16	2011-07-29	Purdue Pharma Lp	Protitelesa, ki se vežejo na celično povezan CA 125/0722P, in postopki za njihovo uporabo
EP1565167B1 (en) *	2002-11-07	2016-06-22	Advanced Bionutrition Corporation	Nutraceuticals and method of feeding aquatic animals
US20050053655A1 (en) *	2003-09-05	2005-03-10	Pharmaceutical Industry Technology And Development Center	Rapid disintegrating tablets (RDTs) for pharmaceutical use and method for preparing the same
WO2005046663A1 (en)	2003-11-04	2005-05-26	Shire Laboratories, Inc.	Compositions of quaternary ammonium containing bioavailability enhancers
DK2210605T3 (en) *	2003-11-04	2017-05-22	Tcd Royalty Sub Llc	Daily single dose doses of trospium.
US20050260258A1 (en)	2003-12-18	2005-11-24	The Texas A&M University System	Use of vitelline protein B as a microencapsulating additive
US20060045865A1 (en) *	2004-08-27	2006-03-02	Spherics, Inc.	Controlled regional oral delivery
WO2006026504A2 (en) *	2004-08-27	2006-03-09	Spherics, Inc.	Mucoadhesive oral formulations of high permeability, high solubility drugs
US7115561B2 (en) *	2004-09-22	2006-10-03	Patterson James A	Medicament composition and method of administration
US9492400B2 (en) *	2004-11-04	2016-11-15	Massachusetts Institute Of Technology	Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals
AR048220A1 (es) *	2005-01-28	2006-04-12	Lkm S A Lab	Arreglo de dispositivos utilizables en la elaboracion de microcapsulas para la liberacion controlada de peptidos y procedimiento de elaboracion de dichas opcionalmente sustituido
WO2007025244A2 (en)	2005-08-25	2007-03-01	Houle Philip R	Treatment systems for delivery of sensitizer solutions
WO2007070682A2 (en)	2005-12-15	2007-06-21	Massachusetts Institute Of Technology	System for screening particles
CA2648099C (en) *	2006-03-31	2012-05-29	The Brigham And Women's Hospital, Inc	System for targeted delivery of therapeutic agents
WO2007137117A2 (en) *	2006-05-17	2007-11-29	Massachusetts Institute Of Technology	Aptamer-directed drug delivery
US9381477B2 (en) *	2006-06-23	2016-07-05	Massachusetts Institute Of Technology	Microfluidic synthesis of organic nanoparticles
US20100144845A1 (en) *	2006-08-04	2010-06-10	Massachusetts Institute Of Technology	Oligonucleotide systems for targeted intracellular delivery
WO2008031780A2 (de) *	2006-09-13	2008-03-20	Basf Se	Verfahren zur herstellung feinteiliger dispersionen
US7731604B2 (en) *	2006-10-31	2010-06-08	Taylor Made Golf Company, Inc.	Golf club iron head
US20100303723A1 (en) *	2006-11-20	2010-12-02	Massachusetts Institute Of Technology	Drug delivery systems using fc fragments
EP2134830A2 (en)	2007-02-09	2009-12-23	Massachusetts Institute of Technology	Oscillating cell culture bioreactor
WO2008124632A1 (en) *	2007-04-04	2008-10-16	Massachusetts Institute Of Technology	Amphiphilic compound assisted nanoparticles for targeted delivery
CA2917512C (en)	2007-10-12	2025-08-05	President And Fellows Of Harvard College	VACCINE NANOTECHNOLOGY
CA2730760A1 (en) *	2008-07-16	2010-01-21	Surmodics Pharmaceuticals, Inc.	Process for preparing microparticles containing bioactive peptides
US8591905B2 (en)	2008-10-12	2013-11-26	The Brigham And Women's Hospital, Inc.	Nicotine immunonanotherapeutics
US8277812B2 (en)	2008-10-12	2012-10-02	Massachusetts Institute Of Technology	Immunonanotherapeutics that provide IgG humoral response without T-cell antigen
ES2584319T3 (es) *	2009-12-04	2016-09-27	Magle Ab	Microesferas de almidón hidrolizado con ligandos endógenos cargados
CN105899197A (zh) *	2013-11-13	2016-08-24	蒂洛特斯制药股份有限公司	多颗粒药物递送系统
DE112016001911A5 (de) *	2015-05-21	2018-01-11	Arnold Lösler	Matrixmembranschicht auf Alginatbasis
US12447166B2 (en)	2016-02-25	2025-10-21	Applied Biological Laboratories, Inc.	Compositions and methods for protecting against airborne pathogens and irritants
CA3014764A1 (en)	2016-02-25	2017-08-31	Applied Biological Laboratories, Inc.	Compositions and methods for protecting against airborne pathogens and irritants

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB2042888B (en) *	1979-03-05	1983-09-28	Teijin Ltd	Preparation for administration to the mucosa of the oral or nasal cavity
US4278206A (en) *	1979-04-13	1981-07-14	Ae Development Corporation	Non-pressurized dispensing system
JPS6034925B2 (ja) *	1979-07-31	1985-08-12	帝人株式会社	持続性鼻腔用製剤およびその製造法
US4389330A (en) *	1980-10-06	1983-06-21	Stolle Research And Development Corporation	Microencapsulation process
US4350840A (en) *	1981-03-20	1982-09-21	Ideal Industries, Inc.	Cord grip
JPS6032714A (ja) *	1983-08-01	1985-02-19	Teijin Ltd	鼻腔粘膜に適用するための安定化された粉末状薬学的組成物
JPS60100516A (ja) *	1983-11-04	1985-06-04	Takeda Chem Ind Ltd	徐放型マイクロカプセルの製造法
JPS61138529A (ja) *	1984-12-10	1986-06-26	Idemitsu Petrochem Co Ltd	サイズ用乳化液の製造方法
ATE66143T1 (de) *	1985-01-11	1991-08-15	Abbott Lab	Feste zubereitung mit langsamer freisetzung.
GB8501015D0 (en) *	1985-01-16	1985-02-20	Riker Laboratories Inc	Drug
US5059587A (en) *	1987-08-03	1991-10-22	Toyo Jozo Company, Ltd.	Physiologically active peptide composition for nasal administration
GB8723846D0 (en) *	1987-10-10	1987-11-11	Danbiosyst Ltd	Bioadhesive microsphere drug delivery system
EP0314863B1 (en) *	1987-11-02	1994-12-07	Baylor College Of Medicine	Use of ICAM-1 or its functional derivatives for the treatment of non-specific inflammation
US5079005A (en) *	1988-06-17	1992-01-07	Gupta Kashmiri L	Time release protein
ES2141076T3 (es)	1988-09-01	2000-03-16	Bayer Ag	Proteina del receptor de rinovirus humano que inhibe la infectividad del virus.
ES2084698T5 (es) *	1989-05-04	2005-03-01	Southern Research Institute	Procedimiento de encapsulacion.
GB2237510B (en) *	1989-11-04	1993-09-15	Danbiosyst Uk	Small particle drug compositions for nasal administration
US5271961A (en) *	1989-11-06	1993-12-21	Alkermes Controlled Therapeutics, Inc.	Method for producing protein microspheres
FR2655732B1 (fr)	1989-12-11	1992-02-07	Snecma	Procede et dispositif de controle du collage d'un nida sur un support.
ES2134762T3 (es)	1990-07-20	1999-10-16	Bayer Ag	Formas multimericas de proteinas receptoras de rinovirus humanos.
US5292499A (en) *	1990-09-11	1994-03-08	University Of Wales College Of Cardiff	Method of preparing medical aerosol formulations including drug dissolved in reverse micelles
WO1993006842A1 (en) *	1991-10-02	1993-04-15	Boehringer Ingelheim Pharmaceuticals, Inc.	Use of intercellular adhesion molecules, and their binding ligands in the treatment of asthma
FR2686250A1 (fr) *	1992-01-16	1993-07-23	Coletica	Compositions injectables contenant en suspension des microcapsules a base de collagene, leur utilisation biomedicale et des compositions pharmaceutiques.
WO1995002416A1 (en) *	1993-07-12	1995-01-26	Virus Research Institute	Hydrogel microencapsulated vaccines
JP3285427B2 (ja) *	1993-08-04	2002-05-27	冷化工業株式会社	エマルション製造装置及び方法
EP2283821A1 (en) *	1993-11-19	2011-02-16	Alkermes, Inc.	Preparation of biodegradable microparticles containing a biologically active agent
GB9414966D0 (en) *	1994-07-26	1994-09-14	Danbiosyst Uk	Pharmaceutical compositions for the nasal administration of antiviral agents
US5840254A (en) *	1995-06-02	1998-11-24	Cdc Technologies, Inc.	Apparatus for mixing fluids for analysis
US5879712A (en) *	1995-06-07	1999-03-09	Sri International	Method for producing drug-loaded microparticles and an ICAM-1 dosage form so produced

1995
- 1995-06-07 US US08/480,624 patent/US5879712A/en not_active Expired - Fee Related
1996
- 1996-06-06 DE DE69636904T patent/DE69636904T2/de not_active Expired - Lifetime
- 1996-06-06 CA CA002224074A patent/CA2224074C/en not_active Expired - Lifetime
- 1996-06-06 EP EP96918456A patent/EP0833614B1/en not_active Expired - Lifetime
- 1996-06-06 AT AT96918456T patent/ATE353631T1/de not_active IP Right Cessation
- 1996-06-06 JP JP50216797A patent/JP4156665B2/ja not_active Expired - Lifetime
- 1996-06-06 WO PCT/US1996/010031 patent/WO1996040069A1/en not_active Ceased
- 1996-06-06 ES ES96918456T patent/ES2281084T3/es not_active Expired - Lifetime
1999
- 1999-03-08 US US09/583,089 patent/US6375985B1/en not_active Expired - Fee Related
2002
- 2002-04-22 US US10/128,147 patent/US7087245B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
US6375985B1 (en)	2002-04-23
US5879712A (en)	1999-03-09
WO1996040069A1 (en)	1996-12-19
JPH11507382A (ja)	1999-06-29
US20030091649A1 (en)	2003-05-15
ES2281084T3 (es)	2007-09-16
EP0833614A4 (en)	2001-07-11
CA2224074C (en)	2009-09-08
ATE353631T1 (de)	2007-03-15
DE69636904D1 (de)	2007-03-29
CA2224074A1 (en)	1996-12-19
US7087245B2 (en)	2006-08-08
EP0833614A1 (en)	1998-04-08
EP0833614B1 (en)	2007-02-14
DE69636904T2 (de)	2007-11-15

Legal Events

Date	Code	Title	Description
2007-04-03	A131	Notification of reasons for refusal	Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070403
2007-07-19	A601	Written request for extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20070627
2007-08-13	A602	Written permission of extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20070813
2007-10-25	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20071003
2007-11-27	A131	Notification of reasons for refusal	Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20071127
2008-03-06	A601	Written request for extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080214
2008-03-24	A602	Written permission of extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080324
2008-04-17	A601	Written request for extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080324
2008-05-12	A602	Written permission of extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080512
2008-05-22	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080425
2008-06-09	TRDD	Decision of grant or rejection written
2008-06-17	A01	Written decision to grant a patent or to grant a registration (utility model)	Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20080617
2008-06-19	A01	Written decision to grant a patent or to grant a registration (utility model)	Free format text: JAPANESE INTERMEDIATE CODE: A01
2008-07-17	A61	First payment of annual fees (during grant procedure)	Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20080710
2008-07-18	FPAY	Renewal fee payment (event date is renewal date of database)	Free format text: PAYMENT UNTIL: 20110718 Year of fee payment: 3
2008-07-18	R150	Certificate of patent or registration of utility model	Free format text: JAPANESE INTERMEDIATE CODE: R150
2011-07-26	FPAY	Renewal fee payment (event date is renewal date of database)	Free format text: PAYMENT UNTIL: 20120718 Year of fee payment: 4
2012-07-12	FPAY	Renewal fee payment (event date is renewal date of database)	Free format text: PAYMENT UNTIL: 20120718 Year of fee payment: 4
2012-07-17	FPAY	Renewal fee payment (event date is renewal date of database)	Free format text: PAYMENT UNTIL: 20130718 Year of fee payment: 5
2013-07-16	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2014-07-15	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2015-07-14	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2016-06-06	EXPY	Cancellation because of completion of term

Publication	Publication Date	Title
CA2224074C (en)	2009-09-08	System and method for producing drug-loaded microparticles
US6207197B1 (en)	2001-03-27	Gastroretentive controlled release microspheres for improved drug delivery
ES2873502T3 (es)	2021-11-03	Proceso de secado por pulverización
NZ507190A (en)	2002-02-01	Incorporation of active substances in carrier matrixes wherein an emulsion is contacted with a fluid gas using an anti-solvent technique
NO176784B (no)	1995-02-20	Fremgangsmåte ved fremstilling av farmasöytisk mikrokapselblanding omfattende overflateaktivt middel
CN101724163B (zh)	2011-09-07	一种壳聚糖衍生物复合微球及其制备方法和应用
Huang et al.	2009	Preparation and pharmacodynamics of low-molecular-weight chitosan nanoparticles containing insulin
Elsayed	2020	Controlled release alginate-chitosan microspheres of tolmetin sodium prepared by internal gelation technique and characterized by response surface modeling
EP1853228A2 (en)	2007-11-14	Process for the manufacture of microspheres or microcapsules
SE517422C2 (sv)	2002-06-04	Farmaceutiskt acceptabel stärkelse
US20010053359A1 (en)	2001-12-20	Drug delivery composition for the nasal administration of antiviral agents
WO2005061095A1 (ja)	2005-07-07	微小球体の製造方法およびその製造装置
JP5513745B2 (ja)	2014-06-04	生物学的分子および担体ポリマーを含む粒子の調製方法
AU2011230601B2 (en)	2015-04-02	Emulsions for microencapsulation comprising biodegradable surface-active block copolymers as stabilizers
US20130101646A1 (en)	2013-04-25	Method of Producing Microparticles
JP2005501810A (ja)	2005-01-20	ポリマーおよび懸濁粒子を含有する電気流体力学的噴霧用の液体形成物
JP7549575B2 (ja)	2024-09-11	経口投与用生物学的ポリマーの製剤
JP2020535224A (ja)	2020-12-03	二重エマルション技術によるマイクロ粒子を調製する方法
AU707462B2 (en)	1999-07-08	Drug delivery composition for the nasal administration of antiviral agents
EP1018335A1 (en)	2000-07-12	Process for formulating granular matrices by precipitation of polmymers in an acidic medium
CZ420399A3 (cs)	2000-04-12	Gastroretenční mikrosféry s regulovaným ulolňováním a zlepšenou dodávkou účinné látky
Pooja et al.	0	MICROBEADS: AN APPROACH TO DELIVER AMINO ACIDS AND PROTIENS